AAVCOVID Vaccine Program Expands Manufacturing Agreements with Gene Therapy Industry Partners Viralgen, Aldevron, and Catalent

The AAVCOVID vaccine program at Massachusetts Eye and Ear and Massachusetts General Hospital has entered into manufacturing agreements with Viralgen, Aldevron and Catalent in order to support manufacturing of the experimental vaccine for clinical studies in the second half of 2020.

Read more

Gene Therapy Program at Penn Medicine Joins AAVCOVID Vaccine Project

The internationally-renowned Gene Therapy Program at the University of Pennsylvania is joining the AAVCOVID vaccine program led by Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham. AAVCOVID is a unique gene-based vaccine candidate designed to protect against SARS-CoV-2, the virus that causes COVID-19.

Read more